<p>Transforming growth factor β-activated kinase 1 (TAK1), a hub kinase at the convergence of multiple signaling pathways, is critical to the development of the central nervous system and has been found to play a role in cell death and apoptosis. TAK1 may have the potential to elucidate mechanisms of cell cycle and neurodegeneration. The Belecky-Adams laboratory has aimed to study TAK1 and its potential roles in cell cycle by studying its role in chick retinal development as well as its possible implication in the progression of diabetic retinopathy (DR). Chapter 3 includes studies that explore TAK1 in a study in chick retinal development and TAK1 in in vitro studies in retinal microglia. Using the embryonic chick, immunohistochemistry for the activated form of TAK1 (pTAK1) showed localization of pTAK1 in differentiated and progenitor cells of the retina. Using an inhibitor or TAK1 activite, (5Z)-7-Oxozeaenol, in chick eye development showed an increase in progenitor cells and a decrease in differentiated cells. This study in chick suggests TAK1 may be a critical player in the regulation of the cell cycle during retinal development. Results from experimentation in chick led to studying the potential role of TAK1 in inflammation and neurodegeneration. TAK1 has previously been implicated in cell death and apoptosis suggesting that TAK1 may be a critical player in inflammatory pathways. TAK1 has been implicated in the regulation of inflammatory factors in different parts of the CNS but has not yet been studied specifically in retina or in specific retinal cells [3, 4]. Chapter 2 includes studies from the Belecky-Adams laboratory of in vitro work with retinal microglia. Retinal microglia were treated with activators and the translocation to the nucleus of a downstream factor of TAK1 was determined: NF-kB. Treatment of retinal microglia in the presence of activators with TAKinib, an inhibitor of TAK1 activation, revealed that TAK1 inhibition reduces the activation of downstream NF-kB. Together this data suggests that TAK1 may be implicated in various systems of the body and further studies on its mechanisms may help elucidate potential therapeutic roles of the kinase.</p>

No description available.

Le vieillissement entraîne plusieurs changements au niveau de la fonction musculaire qui peuvent mener à une perte de la masse musculaire et de sa fonction qu’on appelle sarcopénie. La sarcopénie entraîne une augmentation du risque de chutes et d’hospitalisations qui nuit à la qualité de vie des personnes âgées. Le vieillissement de la population représente un enjeu important au sein de la société en raison de son impact socioéconomique élevé. Plusieurs facteurs contribuent à ce déclin observé au cours du vieillissement, mais un des éléments clés qui y contribue sont des altérations de la jonction neuromusculaire (JNM). La JNM est une synapse tripartite composée de la terminaison nerveuse présynaptique, de la fibre musculaire postsynaptique et des cellules de Schwann périsynaptiques (CSPs), des cellules gliales. Les CSPs jouent un rôle essentiel dans la maintenance, la modulation de la transmission et de la plasticité synaptique et la réparation de la JNM. Plusieurs études effectuées chez le murin ont démontré que la JNM présente des altérations telles que de la dénervation, de la fragmentation du postsynaptique et des signes de modulation et de réparation gliaux au cours du vieillissement. Ces altérations contribuent aux déficits de la fonction neuromusculaire observés lors du vieillissement. La JNM humaine demeure cependant sous-étudiée, particulièrement en considérant sa structure tripartite. Afin de mieux comprendre le vieillissement neuromusculaire chez l’humain, des biopsies du Vastus lateralis ont été effectuées chez 4 jeunes adultes (23-28 ans) et 5 personnes âgées (60-75 ans) sains et actifs. Un marquage immunohistochimique a été effectué sur les biopsies afin d’identifier les trois composantes de base de la JNM et le type de fibre, puis visualiser en microscopie confocale. Des mesures fonctionnelles ont également été prélevées pour chacun des participants âgés. L’analyse des JNMs a permis de démontrer qu’une instabilité de l’innervation de même qu’une relation tripartite divergente se développe avec l’âge. Ces altérations corrèlent également avec un déficit fonctionnel. Dans l’ensemble, notre étude présente des altérations de la JNM humaine au cours du vieillissement ayant un impact sur la fonction neuromusculaire. Elle pourrait permettre de mieux comprendre les mécanismes à la base du vieillissement neuromusculaire pour développer des stratégies d’intervention thérapeutiques efficaces pour limiter l’impact du vieillissement. / Several changes occur in muscular function in aging which can lead to a loss of muscle mass and function called sarcopenia. Sarcopenia can lead to an increased risk of fall and hospitalization and to a poor quality of life. Aging of the population represents an important societal issue due to its high socioeconomic impact. Many factors contribute to the decline of muscular function seen in aging, but alterations of the neuromuscular junctions are a key element leading to sarcopenia. The NMJ is a tripartite synapse composed of the presynaptic nerve terminal, the postsynaptic muscle fiber as well as perisynaptic Schwann cells (PSC), glial cells. PSCs play a key role in maintenance, modulation of synaptic transmission and plasticity as well as repair of the NMJ. Several rodent studies have shown that the NMJ present alterations such as denervation, fragmentation of the postsynaptic and glial-related signs of modulation and repair in aging. These alterations contribute to the neuromuscular deficits observed in aging. However, the NMJ remain widely understudied, particularly when considering its tripartite structure. In order to get a better understanding of neuromuscular aging in humans, biopsies form the Vastus lateralis were performed on 4 young (23-28 years old) and 5 older (60-75 years old) healthy and physically active men. Immunohistochemistry labelling of the NMJ’s main components and type of fibers was performed and then imaged using confocal microscopy. Functional assessment was also measured for each older adult. Analysis of NMJs revealed an instability in the innervation as well as a divergent tripartite relationship in older individuals. These alterations also correlated with neuromuscular deficits. Taken altogether, our study highlights alterations of the NMJ in aging leading to altered neuromuscular function. This could lead to a better understanding of the underlying mechanisms leading to sarcopenia and to develop better therapeutic strategies to limit its impact during aging.

Amyotrophic Lateral Sclerosis (ALS) is an always lethal motor neuron disease with unknown pathogenesis. Inhibitors of the molecular chaperone heat shock protein 90 (Hsp90) have limited neuroprotection in some models of motor neuron degeneration. However the direct effect of Hsp90 inhibition on motor neurons is unknown. Here we show that Hsp90 inhibition induced motor neuron death through activation of the P2X7 receptor. Motor neuron death required phosphatase and tensein homolog (PTEN)-mediated inhibition of the PI3K/AKT pathway leading to Fas receptor activation and caspase dependent death. The relevance of Hsp90 for motor neuron survival was investigated in mutant Cu/Zn superoxide dismutase (SOD) transgenic animal models for ALS. Nitrated Hsp90, a posttranslational modification known to induce cell death (Franco, Ye et al. 2013), was present in motor neurons after intracellular release of zinc deficient (Zn, D83S) and the SOD in which copper binding site was genetically ablated (Q) but not after copper deficient (Cu) wild type SOD. Zn deficient and Q mutant SOD induced motor neuron death in a peroxynitrite mediated and copper dependent mechanism. Nitrated Hsp90 was not detected in the spinal cord of transgenic animals for ALS-mutant SOD animal models until disease onset. Increased nitrated Hsp90 concentrations correlated with disease progression. Addition of Zn or Q SOD to nontransgenic brain homogenate treated with peroxynitrite led to an increase level of nitrotyrosine in comparison to wild type controls. However, in the same samples there was a 2 to 10 time increase in Hsp90 nitration as compared to nitrotyrosine. The selective increase is likely due to the binding of Hsp90 to Zn deficient and Q SOD as oppose to wild type SOD. These results suggest that Hsp90 nitration facilitated by mutant SOD may cause motor neuron degeneration in ALS. Targeted inhibition of nitrated Hsp90 may be a novel therapeutic approach for ALS. An alternative therapeutic strategy is to target the production of survival factors by glial cells. Riluzole is the only FDA approved drug for the treatment of ALS and it shows a small but significant increase in patient lifespan. Our results show that acute riluzole treatment stimulated trophic factor production by astrocytes and Schwann cells. However long-term exposure reversed and even inhibited the production of trophic factors, an observation that may explain the modest increase in patient survival in clinical trials. Discontinuous riluzole treatment can maintain elevated trophic factor levels and prevent trophic factor reduction in spinal cords of nontransgenic animals. These results suggest that discontinuous riluzole administration may improve ALS patient survival. In summary, we demonstrated that Hsp90 has an essential function in the regulation of motor neuron survival. We have also shown that Hsp90 was nitrated in the presence of mutant SOD and was present during symptom onset and increases as disease progresses, which may explain the toxic gain of function of mutant SOD. Finally we demonstrate a biphasic effect of riluzole on trophic factor production and propose changes in administration to improve effects in ALS patients.

Coupling of cells to biomaterials is a prerequisite for most biomedical applications; e.g., neuroelectrodes can only stimulate brain tissue in vivo if the electric signal is transferred to neurons attached to the electrodes’ surface. Besides, cell survival in vitro also depends on the interaction of cells with the underlying substrate materials; in vitro assays such as multielectrode arrays determine cellular behavior by electrical coupling to the adherent cells. In our study, we investigated the interaction of neurons and glial cells with different electrode materials such as TiN and nanocolumnar TiN surfaces in contrast to gold and ITO substrates. Employing single-cell force spectroscopy, we quantified short-term interaction forces between neuron-like cells (SH-SY5Y cells) and glial cells (U-87 MG cells) for the different materials and contact times. Additionally, results were compared to the spreading dynamics of cells for different culture times as a function of the underlying substrate. The adhesion behavior of glial cells was almost independent of the biomaterial and the maximum growth areas were already seen after one day; however, adhesion dynamics of neurons relied on culture material and time. Neurons spread much better on TiN and nanocolumnar TiN and also formed more neurites after three days in culture. Our designed nanocolumnar TiN offers the possibility for building miniaturized microelectrode arrays for impedance spectroscopy without losing detection sensitivity due to a lowered self-impedance of the electrode. Hence, our results show that this biomaterial promotes adhesion and spreading of neurons and glial cells, which are important for many biomedical applications in vitro and in vivo.

No description available.

Biomaterials employed for neural stimulation, as well as brain/machine interfaces, offer great perspectives to combat neurodegenerative diseases, while application of lab-on-a-chip devices such as multielectrode arrays is a promising alternative to assess neural function in vitro. For bioelectronic monitoring, nanostructured microelectrodes are required, which exhibit an increased surface area where the detection sensitivity is not reduced by the self-impedance of the electrode. In our study, we investigated the interaction of neurons (SH-SY5Y) and glial cells (U-87 MG) with nanocolumnar titanium nitride (TiN) electrode materials in comparison to TiN with larger surface grains, gold, and indium tin oxide (ITO) substrates. Glial cells showed an enhanced proliferation on TiN materials; however, these cells spread evenly distributed over all the substrate surfaces. By contrast, neurons proliferated fastest on nanocolumnar TiN and formed large cell agglomerations. We implemented a radial autocorrelation function of cellular positions combined with various clustering algorithms. These combined analyses allowed us to quantify the largest cluster on nanocolumnar TiN; however, on ITO and gold, neurons spread more homogeneously across the substrates. As SH-SY5Y cells tend to grow in clusters under physiologic conditions, our study proves nanocolumnar TiN as a potential bioactive material candidate for the application of microelectrodes in contact with neurons. To this end, the employed K-means clustering algorithm together with radial autocorrelation analysis is a valuable tool to quantify cell-surface interaction and cell organization to evaluate biomaterials’ performance in vitro

Obesity is associated with deficits in cognitive function, particularly within the domain of executive function (EF). EF refers to higher order cognitive processes that regulate our ability to sustain attention, inhibit subconscious tendencies, remember and manipulate information for immediate use, and remain cognitively flexible. Deficits in EF in overweight and obese individuals may impact the success of weight loss and maintenance efforts. Therefore, understanding the biological links between obesity and EF, as well as the ability to reverse EF deficits with weight loss, is imperative. The first study aimed to determine the effect of weight loss in overweight and obese, middle-aged and older adults on serum brain-derived neurotrophic fact (BDNF), S100 calcium binding protein B (S100B), and glial fibrillary acidic protein (GFAP). Serum samples (n=21; 50-75 years, BMI 25-40 kg/m2) were pooled from two prior weight loss studies. Fasting blood measurements were taken before and after 8- or 12-weeks of hypocaloric diet-induced weight loss (1200 or 1500 kcal/d). Body Mass Index (BMI), body weight, waist circumference, and percent body fat (All p<0.001) decreased with weight loss. Serum BDNF (p=0.871), S100B (p=0.898), and GFAP (p=0.506) did not change following weight loss. The second study aimed to determine the correlation between the magnitude of change in serum BDNF, S100B, and GFAP and the magnitude of improvement in EF performance on three computer-based tests. Participants (n=8; 50-75 years, BMI 25-40 kg/m2) completed 4-weeks of hypocaloric diet-induced weight loss (1200 or 1500 kcal/d), followed by 4-weeks of weight maintenance (hypocaloric diet + steps/d goal). Fasting blood and EF measurements were completed at baseline, and weeks 4 and 8. BMI (p=0.001), body weight (p=0.001), waist circumference (p=0.002), and percent body fat (p=0.001) decreased from baseline to week 8. Serum BDNF (p=0.359), S100B (p=0.277), and GFAP (p=0.585) did not change following weight loss. Go/No-Go (GNG) errors of commission (p=0.009) and AX-Continuous Performance Test (AX-CPT) correct response time (p=0.041) decreased following the weight loss. The change in serum GFAP was inversely correlated with GNG errors of omission (r=-0.716, p=0.046) and AX-CPT correct hits (r=-0.737, p=0.037), and positively correlated with AX-CPT correct response time (r=0.859, p=0.006). In conclusion, although weight loss does not influence serum BDNF, S100B, or GFAP levels, it may have a positive effect on inhibitory control in overweight and obese, middle-aged and older adults. Further research is needed to understand the relationship between serum BDNF, S100B, and GFAP and executive function. / Master of Science / Obesity is associated with lower brain function, particularly in executive function (EF). EF refers to advanced thought processes that help to maintain focus, practice self-control, solve problems, and easily switch between tasks. Lower EF in individuals with overweight and obesity may impact the success of weight loss and maintenance efforts. Because of this, understanding body processes that may link obesity and lower EF, as well as the ability to improve EF with weight loss, is very important. The first study aimed to determine the effect of weight loss on blood proteins responsible for brain health: brain-derived neurotrophic fact (BDNF), S100 calcium binding protein B (S100B), and glial fibrillary acidic protein (GFAP). Twenty-one blood samples from overweight and obese, middle-aged and older adults were combined from two completed weight loss studies. In these studies, blood was measured before and after 8- or 12-weeks of a weight loss (low calorie diet;1200 or 1500 Calories per day). Body Mass Index (BMI), body weight, waist circumference, and percent body fat all decreased with weight loss; however, levels of BDNF, S100B, and GFAP in the blood did not change. The second study aimed to determine the relationship between blood BDNF, S100B, and GFAP and performance on three computer-based tests of EF before and after weight loss. Eight overweight and obese, middle-aged and older adults completed 4-weeks of weight loss (low-calorie diet; 1200 or 1500 Calories per day), followed by 4-weeks of weight maintenance. BMI, body weight, waist circumference, and percent body fat all decreased following the weight loss and maintenance intervention (week 8). Blood BDNF, S100B, and GFAP levels did not change, but performance on two EF measures improved: participants made less errors of commission (doing something when not supposed to) and had faster reaction time following the intervention, indicating better self-control. Additionally, greater increases in GFAP were associated with less errors of omission (not doing something when supposed to), fewer correct responses, and slower reaction time. In conclusion, although weight loss did not affect blood BDNF, S100B, or GFAP levels, it may improve self-control in overweight and obese, middle-aged and older adults. Further research is needed to understand the relationship between weight loss, blood proteins of brain health, and EF.

Transgenic Tg2576 mice expressing human amyloid precursor protein (hAPP) with the Swedish mutation are among the most frequently used animal models to study the amyloid pathology related to Alzheimer's disease (AD). The transgene expression in this model is considered to be neuron-specific. Using a novel hAPP-specific antibody in combination with cell type-specific markers for double immunofluorescent labelings and laser scanning microscopy, we here report that-in addition to neurons throughout the brain-astrocytes in the corpus callosum and to a lesser extent in neocortex express hAPP. This astrocytic hAPP expression is already detectable in young Tg2576 mice before the onset of amyloid pathology and still present in aged Tg2576 mice with robust amyloid pathology in neocortex, hippocampus, and corpus callosum. Surprisingly, hAPP immunoreactivity in cortex is restricted to resting astrocytes distant from amyloid plaques but absent from reactive astrocytes in close proximity to amyloid plaques. In contrast, neither microglial cells nor oligodendrocytes of young or aged Tg2576 mice display hAPP labeling. The astrocytic expression of hAPP is substantiated by the analyses of hAPP mRNA and protein expression in primary cultures derived from Tg2576 offspring. We conclude that astrocytes, in particular in corpus callosum, may contribute to amyloid pathology in Tg2576 mice and thus mimic this aspect of AD pathology.

INTRODUÇÃO: As doenças retinianas associadas à neovascularização, tais como a degeneração macular relacionada à idade e as retinopatias diabética e da prematuridade são as principais e mais importantes causas da cegueira em todo o mundo. Nos últimos anos, injeções intravítreas de fármacos com ação antiangiogênica, como o bevacizumabe (BVZ), têm sido de grande valia tanto em pacientes na fase adulta quanto nos recém-natos. Todavia, estudos experimentais in vitro e in vivo sugerem que essas drogas promovam efeitos adversos sobre alguns processos celulares, interferindo diretamente em mecanismos fisiológicos que mantém a homeostase do tecido retiniano, incluindo os mecanismos de proliferação, diferenciação e morte celular. OBJETIVO: investigar o efeito do BVZ nos processos de transcrição e tradução de marcadores da gliose: GFAP e vimentina, de morte celular, caspase-3 e beclina-1, e dos proteoglicanos relacionados à manutenção e desenvolvimento de tecido retiniano: neurocam, fosfacam e sindecam-3. MÉTODOS: Dois modelos experimentais foram usados nesse estudo: 1) linhagem celular de Müller de Glia humana adulta (MIO-M1), cultivada em meio de cultura D-MEM na presença e ausência de BVZ por 12 e 24 horas nas concentrações de 0,25 mg/mL e 0,50 mg/mL e 2) explantes de retinas de ratos 2 dias pós-nascidos submetidos à 0,50 mg/mL da droga por 48 horas. Durante este período foram mantidos a 5% de dióxido de carbono à temperatura de 37°C. A análise de proteínas foi realizada por imunocitohistoquímica e Western Blotting e a expressão de RNAm, pela reação em cadeia da polimerase em tempo real (PCR Real Time). Foi utilizado o Teste de ANOVA - fator único para a comparação entre os grupos controle e tratados com BVZ de um mesmo período (12h ou 24h) e o teste t de Student para a comparação entre as mesmas concentrações de 12h e 24h, e para a comparação entre os grupos controle e tratado com BVZ dos explantes (p < 0,05). RESULTADOS: Nas células MIO-M1, o BVZ, aumentou a expressão gênica e diminui a tradução de VEGF na concentração de 0,50 mg/mL em 24h comparado a 12h. Para o GFAP, houve um aumento da transcrição em 0,50 mg/mL em 24h comparado a 12h e aos outros grupos em 24h. Entretanto, houve diminuição da tradução para estes mesmos períodos e condições. Para a vimentina, houve aumento na transcrição em 0,50 mg/mL após 24h. Os achados de beclina-1 revelaram uma diminuição da transcrição e tradução em 0,25 mg/mL em 24h comparado a 12h. A transcrição entre os grupos do mesmo período aumentou nos grupos tratados com BVZ tanto em 12h quanto em 24h. A tradução da beclina-1 diminuiu em 0,25 mg/mL, mas aumentou em 0,50 mg/mL em 24h em relação à 12h. A comparação entre os grupos de 24h revelou aumento da tradução em 0,50 mg/mL. Para a caspase-3, houve diminuição da transcrição em 0,25 mg/mL e 0,50 mg/mL em 24h em relação a 12h e entre nos grupos tratados com BVZ em 24h. A tradução revelou um aumento em 0,50 mg/mL em 24h em relação a 12h. No fosfacam, houve diminuição da transcrição em 0,50 mg/mL em 24h comparado a 12h e entre os grupos tratados com BVZ e controles para 12h e 24h. A transcrição de neurocam diminuiu em 0,25 mg/mL e 0,50 mg/mL em 24h comparado a 12h e entre os grupos tratados com BVZ e controles em 12h e 24h. A tradução aumentou em 0,50 mg/mL em 24h em relação a 12h, mas diminuiu entre os grupos em 24h. Nos explantes, a transcrição e tradução de VEGF diminuiram no grupo tratado com BVZ após 48h. CONCLUSÃO: Nossos resultados relacionados às células MIO-M1 e ao explante de ratos, in vitro, nos permitem aventar o possível comprometimento ocasionado pela depleção do VEGF pelo BVZ na homeostase do tecido retiniano, in vivo, interferindo nas moléculas envolvidas na morte e diferenciação celular e na neuroproteção em indivíduos em fase adulta e recém-nato / Backgraound: Vasoproliferative retinal disorders such as age-related macular, degeneration, diabetic retinopathy and retinopathy of prematurity are major causes of blindness in the world. In recent years, intravitreal injections of drugs with antiangiogenic action, as bevacizumab, have been very useful for both patients in adulthood and in newborns. However, experimental studies, in vivo and in vitro, suggest that antiangiogenic drugs may promote side effects in cellular proceedings, interfering directly in physiological mechanisms of cellular proliferation, differentiation and death. POURPOSE: Investigate the bevacizumab effects in transcription and translation processes of gliosis, GFAP and vimentin, cellular death markers, caspase-3 and beclin-1, and proteoglycans involved in retinal tissue maintenance and development, neurocan, phosphacan and syndecan-3. METHODS: Two experimental models were used on this research: cellular lineage of adult and human Müller glial cell(MIO-M1) were cultivated on D-MEM medium with 0,25 and 0,50 mg/mL bevacizumab for 12 and 24 hours, and two days old rat retinal explants submitted to 0,50 mg/mL for 48 hours. During this period were stored in laboratory ovens at 5% carbon dioxide pressure and 37 °C average temperature. Molecular techniques were used to evaluate gene expression and protein content. Protein assessments were performed by immunocytochemistry and western blotting analysis, while Real Time PCR was used to measure mRNA content. ANOVA tests one factor were applied to compare the control and BVZ groups of the same period (12h or 24h) and t test from Student to compare the same conditions of 12h and 24h, and to compare the control and BVZ retinal explants groups (p<0.05). RESULTS: At MIO-M1 cells, BVZ increased the gene expression and reduced the translation of VEGF at concentration of 0.50 mg / mL in 24 hours compared to 12 hours. For GFAP, there was an increase of transcription at 0.50 mg / mL in 24 hours compared to 12 hours and to the other groups at 24 hours. However, there was a decrease in translation for these same periods and conditions. For vimentin, there was an increase in transcription at 0.50 mg / mL after 24 hours. The beclin-1 findings revealed a decrease of transcription and translation at 0.25 mg / ml compared at 24 h compared to 12h. Transcription among groups increased in BVZ treated groups at 12h and 24h. The translation of beclin-1 decreased at 0.25 mg / ml, but increased at 0.50 mg / mL at 24 hours compared to 12 hours. The comparison between the groups at 24h revealed an increased in translation at 0.50 mg / mL. For caspase-3, there was a decrease in transcription at 0.25 mg / ml and 0.50 mg / ml at 24 compared to 12 hours and among BVZ treated groups at 24h. Translation revealed an increase at 0.50 mg / mL at 24 hours compared to 12 hours. For fosfacam, there was a decreased in transcription at 0.50 mg / mL in 24 hours compared to 12 hours and among BVZ treated groups and controls at 12h and 24h. The transcription of neurocam decreased at 0.25 mg / ml and 0.50 mg / ml at 24 hours compared to 12 hours and among BVZ treated groups and controls at 12h and 24h. Translation increased at 0.50 mg / mL at 24 compared to 12 hours, but decreased among the groups at 24 hours. For explants, transcription and translation of VEGF decreased in the BVZ group treated after 48h. CONCLUSION: Our results related to the MIO-M1 cells and explants of rats,in vitro, allow us to suggest the possible impairment caused by depletion of VEGF by BVZ in the homeostasis of retinal tissue, in vivo, interfering in the molecules involved in cell death and cell differentiation and neuroprotection in individuals in adulthood and newborns